Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
290 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2015', provides an overview of the Metastatic Renal Cell Carcinoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Metastatic Renal Cell Carcinoma Overview 8 Therapeutics Development 9 Pipeline Products for Metastatic Renal Cell Carcinoma - Overview 9 Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis 10 Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies 11 Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 13 Metastatic Renal Cell Carcinoma - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Metastatic Renal Cell Carcinoma - Products under Development by Companies 18 Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 21 Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development 22 Acceleron Pharma, Inc. 22 Amgen Inc. 23 Angiogene Pharmaceuticals Limited 24 Argos Therapeutics, Inc. 25 Astellas Pharma Inc. 26 Bayer AG 27 Beta Pharma, Inc. 28 Bionomics Limited 29 Cellceutix Corporation 30 Celldex Therapeutics, Inc. 31 Cerulean Pharma, Inc. 32 Dr. Reddy's Laboratories Limited 33 EirGenix Inc. 34 Eisai Co., Ltd. 35 Eli Lilly and Company 36 Epirus Biopharmaceuticals, Inc. 37 Exelixis, Inc. 38 Genor BioPharma Co., Ltd. 39 GlaxoSmithKline Plc 40 Hetero Drugs Limited 41 Hospira, Inc. 42 immatics biotechnologies GmbH 43 Immune Design Corp. 44 Immunicum AB 45 Inbiopro Solutions Pvt. Ltd. 46 Mabion SA 47 Merck & Co., Inc. 48 NewLink Genetics Corporation 49 Novartis AG 50 Oncobiologics, Inc. 51 Ono Pharmaceutical Co., Ltd. 52 Panacea Biotec Limited 53 Peloton Therapeutics, Inc. 54 Prima BioMed Ltd. 55 Rexahn Pharmaceuticals, Inc. 56 Seattle Genetics, Inc. 57 Syndax Pharmaceuticals, Inc. 58 TVAX Biomedical, Inc. 59 Metastatic Renal Cell Carcinoma - Therapeutics Assessment 60 Assessment by Monotherapy Products 60 Assessment by Combination Products 61 Assessment by Target 62 Assessment by Mechanism of Action 66 Assessment by Route of Administration 69 Assessment by Molecule Type 71 Drug Profiles 73 AGS-16C3F - Drug Profile 73 aldesleukin - Drug Profile 74 bevacizumab biosimilar - Drug Profile 75 bevacizumab biosimilar - Drug Profile 76 bevacizumab biosimilar - Drug Profile 77 bevacizumab biosimilar - Drug Profile 78 bevacizumab biosimilar - Drug Profile 79 bevacizumab biosimilar - Drug Profile 80 bevacizumab biosimilar - Drug Profile 81 bevacizumab biosimilar - Drug Profile 82 bevacizumab biosimilar - Drug Profile 83 bevacizumab biosimilar - Drug Profile 84 bevacizumab biosimilar - Drug Profile 85 BNC-105 - Drug Profile 86 BPI-3119 - Drug Profile 88 cabozantinib s-malate - Drug Profile 89 capmatinib - Drug Profile 93 Cell Therapy for Metastatic Renal Cell Carcinoma - Drug Profile 96 CRLX-101 - Drug Profile 97 dalantercept - Drug Profile 100 Dendritic Cell Therapy for Metastatic Renal Cell Carcinoma and Melanoma - Drug Profile 102 entinostat - Drug Profile 103 everolimus - Drug Profile 107 G-305 - Drug Profile 113 IBPM-002BZ - Drug Profile 115 IMA-901 - Drug Profile 116 IMP-321 - Drug Profile 118 Intuvax - Drug Profile 120 KM-3174 - Drug Profile 124 lenvatinib - Drug Profile 128 LY-2510924 - Drug Profile 133 Monoclonal Antibody Conjugated to Target Cells Expressing Antigen G250 for Renal Cell Carcinoma - Drug Profile 135 nivolumab - Drug Profile 136 Orellanine - Drug Profile 143 panobinostat - Drug Profile 144 pazopanib hydrochloride + pembrolizumab - Drug Profile 150 pembrolizumab - Drug Profile 151 PT-2385 - Drug Profile 160 radium Ra 223 dichloride - Drug Profile 161 Recombinant Protein for Oncology - Drug Profile 164 rilotumumab - Drug Profile 165 rocapuldencel-t - Drug Profile 167 RX-0201 - Drug Profile 170 SGN-CD70A - Drug Profile 172 trebananib - Drug Profile 173 TVI-Kidney-1 - Drug Profile 176 varlilumab - Drug Profile 177 ZD-6126 - Drug Profile 179 Metastatic Renal Cell Carcinoma - Recent Pipeline Updates 180 Metastatic Renal Cell Carcinoma - Dormant Projects 273 Metastatic Renal Cell Carcinoma - Discontinued Products 276 Metastatic Renal Cell Carcinoma - Product Development Milestones 277 Featured News & Press Releases 277 Appendix 285 Methodology 285 Coverage 285 Secondary Research 285 Primary Research 285 Expert Panel Validation 285 Contact Us 285 Disclaimer 286
List of Tables
Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2015 13 Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2015 14 Number of Products under Development by Companies, H2 2015 15 Number of Products under Investigation by Universities/Institutes, H2 2015 17 Comparative Analysis by Late Stage Development, H2 2015 18 Comparative Analysis by Clinical Stage Development, H2 2015 19 Comparative Analysis by Early Stage Development, H2 2015 20 Comparative Analysis by Unknown Stage Development, H2 2015 21 Products under Development by Companies, H2 2015 22 Products under Development by Companies, H2 2015 (Contd..1) 23 Products under Development by Companies, H2 2015 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2015 25 Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2015 26 Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2015 27 Metastatic Renal Cell Carcinoma - Pipeline by Angiogene Pharmaceuticals Limited, H2 2015 28 Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2015 29 Metastatic Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2015 30 Metastatic Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2015 31 Metastatic Renal Cell Carcinoma - Pipeline by Beta Pharma, Inc., H2 2015 32 Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2015 33 Metastatic Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2015 34 Metastatic Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2015 35 Metastatic Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H2 2015 36 Metastatic Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 37 Metastatic Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2015 38 Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2015 39 Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2015 40 Metastatic Renal Cell Carcinoma - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 41 Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2015 42 Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H2 2015 43 Metastatic Renal Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2015 44 Metastatic Renal Cell Carcinoma - Pipeline by Hetero Drugs Limited, H2 2015 45 Metastatic Renal Cell Carcinoma - Pipeline by Hospira, Inc., H2 2015 46 Metastatic Renal Cell Carcinoma - Pipeline by immatics biotechnologies GmbH, H2 2015 47 Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2015 48 Metastatic Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2015 49 Metastatic Renal Cell Carcinoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 50 Metastatic Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2015 51 Metastatic Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2015 52 Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2015 53 Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2015 54 Metastatic Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2015 55 Metastatic Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 56 Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2015 57 Metastatic Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2015 58 Metastatic Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2015 59 Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015 60 Metastatic Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H2 2015 61 Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015 62 Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2015 63 Assessment by Monotherapy Products, H2 2015 64 Assessment by Combination Products, H2 2015 65 Number of Products by Stage and Target, H2 2015 67 Number of Products by Stage and Mechanism of Action, H2 2015 71 Number of Products by Stage and Route of Administration, H2 2015 74 Number of Products by Stage and Molecule Type, H2 2015 76 Metastatic Renal Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2015 184 Metastatic Renal Cell Carcinoma - Dormant Projects, H2 2015 277 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2015 278 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2015 279 Metastatic Renal Cell Carcinoma - Discontinued Products, H2 2015 280
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
